Silence Therapeutics Announces Proposed Public Offering of $150 Million of American Depositary Shares August 10, 2026 Silence Therapeutics plc (“Silence” or the “Company”), a global clinical-stage biotechnology company developing novel short interfering RNA (“siRNA”) therapies, today announced that it has commenced an underwritten public offering of approximately $150 million of its American Depositary Shares (“ADSs”), each representing three ordinary shares of £0.05 each in the capital of the Company, in the [...]
Silence Therapeutics Announces Positive Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera, Supporting its Potential Best-in-Class Profile August 10, 2026 Trial met its primary endpoint, with a significantly higher proportion of clinical responders on divesiran (88%) compared to placebo (19%); placebo-adjusted response rate = 69% Both divesiran dose groups showed substantial primary endpoint efficacy; 93.8% response rate at Q6W and 81.3% response rate at Q12W Divesiran was observed to be well tolerated with no new safety findings Phase 3 PV trial evaluating divesiran Q12W vs. placebo anticipated to initiate in 1H’27 Investor conference call and webcast to be held today, August 10, 2026 at 8:00 a.m. ET
CoStar Data Shows Strong Prelet Activity Driving UK Lab Space Demand to a Record High August 6, 2026 GSK’s landmark life sciences prelet drove UK laboratory space demand to a new record, according to data from CoStar, a global leading provider of online real estate marketplaces, information and analytics in the property markets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260806333297/en/ Rolling four-quarter take-up exceeded 1.2 million square feet in [...]
Everfox Reaffirms Commitment to UK Armed Forces Covenant August 5, 2026 Company’s Pledge Follows on Heels of Receiving Defence Employer Recognition Scheme Silver Award
Lehman Brothers Treasury Considers Sale and Final Wind-Down August 3, 2026 Lehman Brothers Treasury Co. B.V. in liquidation (“LBT”) today, through its U.S. counsel Herbert Smith Freehills Kramer (USA) LLP, announced that LBT is considering a final wind-down of its estate. In connection therewith, LBT has retained Seaport Loan Products LLC as its exclusive placement agent in connection with the potential sale of LBT’s principal remaining [...]
AngloGold Ashanti Q2 30 June 2026 Earnings Release and Dividend Declaration July 31, 2026 Q2 2026 EBITDA*(5) +46% to $2.0bn • Q2 2026 free cash flow* +36% to $727m • YTD free cash flow* $1.9bn • Q2 2026 interim dividend of $364m, or 72 cps • Proposed $2.0bn share repurchase programme approved • Net cash*(5) of $991m after debt buyback
KBRA Releases Research – KBRA-Rated European RMBS Exposure to Wildfires in Spain July 31, 2026 KBRA releases research assessing the potential exposure of KBRA-rated European residential mortgage-backed securities (RMBS) transactions to the ongoing wildfires in Spain. Spain is confronting an exceptionally severe wildfire season, with approximately 173,000 hectares burnt from the start of the year through 28 July, nearly six times the amount recorded over the same period in 2025. [...]
Kingswood Capital Management Raises $4 Billion Across Two Oversubscribed Middle-Market Funds July 30, 2026 The firm’s fourth institutional fundraise more than doubles its assets under management, reaching over $7 billion
Mary Kay Releases 2026 Sustainability Report Highlighting Transformative Progress Across Social, Economic, and Environmental Impact Globally July 30, 2026 Beauty Leader Ranked #8 on Forbes’ 2026 Best Brands For Social Impact List
Iksuda receives US FDA IND clearance for IKS04 July 30, 2026 CA242-directed ADC approved for assessment in Phase 1 trials in patients with GI cancers The ‘IKS04 Regimen’ is an innovative dosing approach for an ADC which is employed to overcome the challenge of solid tumour penetration for high-potency payloads